Table 1.
Comparison between LCC and other NSCLCs
| Variables | LCC | LCNEC | BSC | SCC | ADE |
|---|---|---|---|---|---|
| Total, n (%) | 3197 (100) | 1111 (100) | 189 (100) | 40 216 (100) | 59 772 (100) |
| Age, n (%) | |||||
| ≤70 | 1931 (60.4) | 748 (67.3)* | 91 (48.1)* | 21 141 (52.6)* | 36 400 (60.9) |
| >70 | 1266 (39.6) | 363 (32.7) | 98 (51.9) | 19 075 (47.4) | 23 372 (39.1) |
| Sex, n (%) | |||||
| Female | 1306 (40.9) | 504 (45.4)* | 77 (40.7) | 14 904 (37.1)* | 31 103 (52.0)* |
| Male | 1891 (59.1) | 607 (54.6) | 112 (59.3) | 25 312 (62.9) | 28 669 (48.0) |
| Race, n (%) | |||||
| White | 2571 (80.4) | 941 (84.7)* | 159 (84.1) | 33 591 (83.5)* | 47 331 (79.2)* |
| Black | 461 (14.4) | 129 (11.6) | 17 (9.0) | 4591 (11.4) | 7128 (11.9) |
| Others | 165 (5.2) | 41 (3.7) | 13 (6.9) | 2034 (5.1) | 5313 (8.9) |
| Pathological differentiation, n (%) | |||||
| Well/moderately | 51 (1.6) | 41 (3.7)* | 27 (14.3)* | 17 609 (43.8)* | 29 110 (48.7)* |
| Poorly/undifferentiated | 3146 (98.4) | 1070 (96.3) | 162 (85.7) | 22 607 (56.2) | 30 662 (51.3) |
| Primary, n (%) | |||||
| Upper lobe | 1861 (58.2) | 664 (59.8) | 92 (48.7)* | 22 401 (55.7)* | 35 398 (59.2)* |
| Middle lobe | 139 (4.3) | 51 (4.6) | 10 (5.3) | 1500 (3.7) | 2897 (4.8) |
| Lower lobe | 761 (23.8) | 268 (24.1) | 71 (37.6) | 11 670 (29.0) | 16 246 (27.2) |
| Others | 436 (13.6) | 128 (11.5) | 16 (8.5) | 4645 (11.6) | 5231 (8.8) |
| T, n (%) | |||||
| T1 | 602 (18.8) | 292 (26.3)* | 53 (28.0)* | 7693 (19.1) | 17 149 (28.7)* |
| T2 | 919 (28.7) | 302 (27.2) | 61 (32.3) | 11 337 (28.2) | 16 933 (28.3) |
| T3 | 549 (17.2) | 186 (16.7) | 36 (19.0) | 6936 (17.2) | 9777 (16.4) |
| T4 | 1127 (35.3) | 331 (29.8) | 39 (20.6) | 14 250 (35.4) | 15 913 (26.6) |
| N, n (%) | |||||
| N0 | 1331 (41.6) | 561 (50.5)* | 121 (64.0)* | 18 900 (47.0)* | 28 216 (47.2)* |
| N1 | 317 (9.9) | 132 (11.9) | 26 (13.8) | 4619 (11.5) | 6231 (10.4) |
| N2 | 1182 (37.0) | 317 (28.5) | 36 (19.0) | 13 253 (33.0) | 19 259 (32.2) |
| N3 | 367 (11.5) | 101 (9.1) | 6 (3.2) | 3444 (8.6) | 6066 (10.1) |
| M, n (%) | |||||
| M0 | 1886 (59.0) | 726 (65.3)* | 157 (83.1)* | 29 134 (72.4)* | 36 318 (60.8) |
| M1 | 1311 (41.0) | 385 (34.7) | 32 (16.9) | 11 082 (27.6) | 23 454 (39.2) |
| Stage, n (%) | |||||
| I | 525 (16.4) | 295 (26.6)* | 78 (41.3)* | 9053 (22.5)* | 16 375 (27.4)* |
| II | 320 (10.0) | 154 (13.9) | 35 (18.5) | 5503 (13.7) | 6143 (10.3) |
| III | 1041 (32.6) | 277 (24.9) | 44 (23.3) | 14 578 (36.2) | 13 800 (23.1) |
| IV | 1311 (41.0) | 385 (34.7) | 32 (16.9) | 11 082 (27.6) | 23 454 (39.2) |
| Surgery, n (%) | |||||
| No | 2131 (66.7) | 530 (47.7)* | 59 (31.2)* | 25 533 (63.5)* | 34 003 (56.9)* |
| Yes | 1066 (33.3) | 581 (52.3) | 130 (68.8) | 14 683 (36.5) | 25 769 (43.1) |
| Chemotherapy, n (%) | |||||
| No | 1805 (56.5) | 515 (46.4)* | 129 (68.3)* | 23 194 (57.7) | 33 114 (55.4) |
| Yes | 1392 (43.5) | 596 (53.6) | 60 (31.7) | 17 022 (42.3) | 26 658 (44.6) |
| Radiotherapy, n (%) | |||||
| No | 1834 (57.4) | 731 (65.8)* | 142 (75.1)* | 22 730 (56.5) | 38 121 (63.8)* |
| Yes | 1363 (42.6) | 380 (34.2) | 47 (24.9) | 17 486 (43.5) | 21 651 (36.2) |
| Overall survival (months)† | |||||
| Median | 8.0 | 15.0* | 35.0* | 13.0* | 19.0* |
| 95% Confidence interval | 7.4–8.6 | 13.3–16.7 | 25.5–44.5 | 12.7–13.3 | 18.6–19.4 |
P‐values were all less than 0.05 in the comparison of five pathological types.
*P‐value <0.0125 (corrected α value = 0.05/4 = 0.0125) when compared with LCC using Chi‐squared tests except †Log‐rank tests.
ADE, adenocarcinoma; BSC, basaloid squamous cell carcinoma; LCC, large cell carcinoma; LCNEC, large cell neuroendocrine carcinoma; NSCLC, non‐small cell lung cancer; SCC, squamous cell carcinoma.